SCHEMBL958671

SCHEMBL958671

C=CCCc1cc(Cl)nc(-c2ccccc2C(F)(F)F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.41
CTSS P25774 1/20 0.38
USP1 O94782 9/20 0.38
WDR48 Q8TAF3 9/20 0.38
CYP1A2 P05177 6/20 0.36
CYP2D6 P10635 4/20 0.36
CYP2C19 P33261 4/20 0.36
CYP2C9 P11712 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
RECQL P46063 1/20 0.36
TRPA1 O75762 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
CYP3A4 P08684 4/20 0.35
TSHR P16473 3/20 0.35
HSD17B10 Q99714 3/20 0.35
ALOX15 P16050 1/20 0.35
MAPK1 P28482 1/20 0.35
HIF1A Q16665 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27577764 0.81 CTSK (0.50) CTSKCTSSUSP1WDR48CYP1A2
SCHEMBL786418 0.74 HSP90AA1 (0.54) USP1WDR48CYP1A2CYP2D6CYP2C19
SCHEMBL785491 0.74 KDM4E (0.49) USP1WDR48CYP1A2CYP2D6CYP2C19
SCHEMBL3105256 0.74 TAS2R14 (0.44) USP1WDR48CYP1A2CYP2D6CYP2C19
SCHEMBL958460 0.73 PIP4K2C (0.44) USP1WDR48CYP1A2CYP2D6CYP2C19
SCHEMBL786422 0.73 HSD11B1 (0.41) USP1WDR48CYP1A2CYP2D6CYP2C19
SCHEMBL959115 0.73 POLB (0.41) CTSKHSD17B10KMT2A
SCHEMBL786243 0.73 KMT2A (0.60) USP1WDR48CYP1A2CYP2D6CYP2C19
SCHEMBL785490 0.71 CCR1 (0.47) CYP1A2CYP2D6CYP2C19CYP2C9CYP3A4
SCHEMBL958107 0.71 CYP1A2 (0.44) USP1WDR48CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872129-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 US disclosed
US-20090118278-A1 COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-07 US disclosed
US-7491730-B2 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-17 US disclosed
EP-1739087-A1 Pyrazole compositions useful as inhibitors of gsk-3 Vertex Pharmaceuticals Incorporated (US) 2007-01-03 EP disclosed
EP-1532145-B1 PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMA (US) 2006-09-13 EP disclosed
EP-1532145-A1 PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 Vertex Pharmaceuticals Incorporated (US) 2005-05-25 EP disclosed
US-20040039007-A1 Compositions useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2004-02-26 US disclosed
WO-2004013140-A1 PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118278-A1 COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 GSK3B, GSK3A, GSKIP CTSK 3136/4885CTSS 4552/4885USP1 3259/4885
US-20040039007-A1 Compositions useful as inhibitors of GSK-3 GSK3A, GSK3B, GSKIP CTSK 3428/4885CTSS 4628/4885USP1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.